Cargando…
Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-D...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872867/ https://www.ncbi.nlm.nih.gov/pubmed/33585132 http://dx.doi.org/10.7759/cureus.12646 |
_version_ | 1783649272204361728 |
---|---|
author | Rouf, Siham Rbiai, Najwa Baibai, Kaoutar Berrich, Jamal Bouchentouf, Toumi Rahmoun, Mohammed Abda, Naima Latrech, Hanane |
author_facet | Rouf, Siham Rbiai, Najwa Baibai, Kaoutar Berrich, Jamal Bouchentouf, Toumi Rahmoun, Mohammed Abda, Naima Latrech, Hanane |
author_sort | Rouf, Siham |
collection | PubMed |
description | Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 ± 3 years. Over a six months’ period of the study, the mean HbA1c level decreased from 8.3 ± 0.8% to 7.0 ± 0.5 % with a reduction in mild hypoglycemic events’ frequency from 5 ± 3 to 1 ± 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 ± 0.5 to 5 ± 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events. |
format | Online Article Text |
id | pubmed-7872867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-78728672021-02-11 Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study Rouf, Siham Rbiai, Najwa Baibai, Kaoutar Berrich, Jamal Bouchentouf, Toumi Rahmoun, Mohammed Abda, Naima Latrech, Hanane Cureus Endocrinology/Diabetes/Metabolism Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 ± 3 years. Over a six months’ period of the study, the mean HbA1c level decreased from 8.3 ± 0.8% to 7.0 ± 0.5 % with a reduction in mild hypoglycemic events’ frequency from 5 ± 3 to 1 ± 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 ± 0.5 to 5 ± 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events. Cureus 2021-01-12 /pmc/articles/PMC7872867/ /pubmed/33585132 http://dx.doi.org/10.7759/cureus.12646 Text en Copyright © 2021, Rouf et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Endocrinology/Diabetes/Metabolism Rouf, Siham Rbiai, Najwa Baibai, Kaoutar Berrich, Jamal Bouchentouf, Toumi Rahmoun, Mohammed Abda, Naima Latrech, Hanane Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study |
title | Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study |
title_full | Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study |
title_fullStr | Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study |
title_full_unstemmed | Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study |
title_short | Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study |
title_sort | feasibility and efficiency of a novel bolus calculator (if-diabete) for patients with type 1 diabetes: a nonrandomized single-arm pilot study |
topic | Endocrinology/Diabetes/Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872867/ https://www.ncbi.nlm.nih.gov/pubmed/33585132 http://dx.doi.org/10.7759/cureus.12646 |
work_keys_str_mv | AT roufsiham feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT rbiainajwa feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT baibaikaoutar feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT berrichjamal feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT bouchentouftoumi feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT rahmounmohammed feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT abdanaima feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy AT latrechhanane feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy |